• Combine the infectious disease research capability of Institut Pasteur Korea with Noul’s AI-based diagnosis platform, miLab
  • Accelerate the development of diagnostic techniques for major tropical infectious diseases such as malaria, leishmaniasis, and Chagas disease
noul-pasteur mou

[Photo] Chanyang Lim, the CEO of Noul (left) and Dr. Youngmee Jee, the CEO of IPK,
exchanged a memorandum of understanding at Institut Pasteur Korea on the 11th.

June 15, 2021 – Noul Co., Ltd. and Institut Pasteur Korea (IPK) signed a memorandum of understanding for mutual exchange and research cooperation at the IPK located in Pangyo, Gyeonggi-do. The signing of this MOU was carried out in recognition of the need for a close cooperation to develop innovative diagnostic techniques for tropical infectious diseases.

Through the MOU, the two organizations plan to actively conduct joint research and exchange academic information with the aim of contributing to the eradication of diseases that threaten human health. Specifically, they will cooperate on developing diagnostic techniques for protozoan tropical diseases, such as malaria, leishmaniasis, and Chagas disease, exchange of academic information, joint use of equipment and facilities, and etc.

Through this research collaboration, Noul plans to spur further research on malaria diagnosis and blood cell analysis using its AI-based diagnostic platform miLab™. miLab is also used for sample preparation and automated analysis related to various infectious diseases, new drug development screening, and etc. Noul’s miLab is an AI-based blood diagnostic medical device that fully automates sample preparation, imaging, and analysis. Since its launch in 2020, it has secured leading domestic and foreign institutions such as the Korea Disease Control and Prevention Agency and global pharmaceutical companies as its major customers, broadening its scope through market expansion.

Chanyang Lim, the CEO of Noul Co., Ltd., revealed the meaning behind the collaboration by saying, “Through cooperation with IPK, which is advancing cutting-edge techniques in international infectious disease research, we expect Noul miLab’s unique and outstanding Next Generation Staining and Immunostaining (NGSI), blood cell imaging, and analysis technology to be applied to the diagnosis of major tropical infectious diseases. It is part of the effort to go beyond the limitations of medical resources in order to streamline diagnosis and improve access to medical care.”

Dr. Youngmee Jee, the CEO of IPK, said, “Combining IPK’s expertise in infectious disease and the Institut Pasteur International Network (IPIN) with Noul’s innovative diagnostic technology will enable us to accelerate the development of practical and reliable diagnostic techniques.” She then revealed, “International cooperation efforts will also be made to ensure that excellent diagnostic techniques can be used effectively in medical fields in developing countries where neglected infectious diseases are prevalent.”

IPK is carrying out multifaceted research and global cooperation to combat neglected infectious diseases. In particular, throughout the ongoing research collaboration with the Drugs for Neglected Diseases initiative (DNDi) since 2009, IPK has contributed to the acceleration of new drug development by deriving drug candidates for leishmaniasis and Chagas disease. In addition, participating in the international joint research supported by the Spanish non-profit foundation la Caixa, IPK is carrying out natural product drug discovery for leishmaniasis and Chagas disease.

Noul’s miLab is an AI-based blood diagnosis platform that is a product fused with NGSI technology to stain cells with a single stamping without the need for liquid, a cartridge with excellent scalability, and AI with excellent performance that reproduces the analysis work of a microscopist. In April 2021, the cartridge and platform used for malaria diagnosis passed the European medical device certification (CE-IVD), confirming its safety and effectiveness.

# # #